Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1988-08-05
1991-08-13
Griffin, Ronald W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 46, 536 24, 536 26, 424 43, 424433, 424436, 424464, A61K 3170, C07H 1916, C07H 19173
Patent
active
050396676
ABSTRACT:
A method is disclosed for the treatment of hepadnavirus infection in animals. Animals infected with duck hepatitis B virus may be treated with the 2',3'-dideoxynucleoside of adenine, guanine, hypoxanthine, 2,6-diaminopurine or various analogs of substituted purines. Several purine 2',3'-dideoxynucleosides inhibit duck hepatitis B virus in hepatocyte culture >99% at 1 .mu.g/ml. Potent in vivo efficacy of the 2,6-diaminopurine 2',3'-dideoxynucleoside for clearance of duck hepatitis B virus from the sera of Pekin ducks is demonstrated. The selective effect on hepadnavirus replication by the purine 2',3'-dideoxynucleosides is based on the discovery of an unexpected sensitivity of hepadnavirus to purine 2',3'-dideoxynucleoside analogs. These compounds present a new antiviral therapy of acute or persistent hepadnavirus infections.
REFERENCES:
Miller et al., "Hepatitis B Virus Particles of Plasma and Liver Contain Viral DNA-RNA Hybrid Molecules," Virology (1984), 139:53-63.
Wagar et al., "Effects of 2',3'-Dideoxynucleosides on Mammalian Cells and Viruses," J. Cell. Physiol. (1984), 121:402-408.
Tsiquaye et al., "Suramin Inhibits Duck Hepatitis B Virus DNA Polymerase Activity," J. Hepatol. (1985), 1:663-669.
Lien et al., "Initiation and Termination of Duck Hepatitis B Virus DNA Synthesis During Virus Maturation," J. Virol. (1987), 61:3832-3840.
Will et al., "Replication Strategy of Human Hepatitis B Virus," J. Virol. 61:904-911.
Loke et al., "Suramin Treatment for Chronic Active Hepatitis B--Toxic and Ineffective," J. Med. Virol. (1987), 21:97-99.
Haritani et al., "Effect of 3'-Azido-3'-Deoxythymidine on Replication of Duck Hepatitis B Virus in vivo and in vitro," J. Med. Virol. (1989), 29:244-248.
Farraye et al., "Preliminary Evidence that Azidothymidine Does Not Affect Hepatitis B Virus Replication in Acquired Immunodeficiency Syndrome (AIDS) Patients," J. Med. Virol. (1989), 29:266-267.
Ueda et al., "Short Communications: An in vitro System for Screening Anti-Hepatitis B Virus Drugs," Virol. (1989), 169:213-216.
Kassianides et al., "Inhibition of Duck Hepatitis B Virus Replication by 2',3'-Dideoxycytidine," Gastroenterol. (1989), 97:1275-1280.
Lee et al., "In vitrol and In vivo Comparison of the Abilities of Purine and Pyrimidine 2',3'-Dideoxynucleosides to Inhibit Duck Hepadnavirus," Antimicrob. Agents and Chemother. (1989), 33:336-339.
Suzuki et al., "Inhibition of Duck Hepatitis B Virus Replication by Purine 2',3'-Dideoxynucleosides," Biochem. and Biophys. Res. Comm. (1988), 156:1144-1151.
Tiollais et al., "The Hepatitis B Virus," Nature (1985), 317:489-495.
Zukerman, "Screening of Antiviral Drugs for Hepadna Virus Infection in Pekin Ducks: A Review," J. Virol. Meth. (1987), 17:119-126.
Robins Morris J.
Suzuki Satoru
Tyrrell David L. J.
Crane L. Eric
Griffin Ronald W.
The Governors of the University of Alberta
LandOfFree
Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucle does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucle, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antiviral therapy for hepatitis B with 2',3'-dideoxypurine nucle will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1527404